---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-107011"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:18:33.218623+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cullinan Therapeutics receives Australian HREC approval to start Phase 1 SLE trial of CLN-978

## Summary
- HREC approval in Australia to initiate global Phase 1 trial of CLN-978 for systemic lupus erythematosus (SLE).
- CLN-978 is a CD19xCD3 bispecific T cell engager designed for off-the-shelf access and convenient dosing.
- SLE affects ~430,000 people globally; current treatments rarely induce treatment-free remission.
- Company also submitted IND to U.S. FDA for this study on September 16, 2024.
- Trial will assess safety, pharmacokinetics, and initial clinical activity in multiple countries.

## SEC filing metadata
- accession: 0000950170-24-107011
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024107011/0000950170-24-107011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024107011/cgem-20240917.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-107011
- JSON: https://secwatch.observer/filing/0000950170-24-107011.json
- Plain text: https://secwatch.observer/filing/0000950170-24-107011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.